Blood Res (2025) 60:2
Published online January 8, 2025
https://doi.org/10.1007/s44313-024-00052-4
© The Korean Society of Hematology
Correspondence to : Mengying Zeng
464469565@qq.com
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
A 75-year-old male was admitted to the hospital with a recurrent fever lasting over a month. Physical examination revealed involuntary tremors in both hands and multiple rashes with apparent bleeding in both lower limbs. Laboratory test results showed leukocytes at 13.1 × 109/L, hemoglobin at 114 g/L, platelets at 108 × 109/L, and elevated levels of lactate dehydrogenase, triglycerides(3.66 mmol/L), ferritin (2745 ng/ml), and soluble interleukin-2 receptor (sIL-2R; 34,170 pg/ml). Fluorodeoxyglucose positron emission tomography (FDG-PET) revealed splenomegaly with increased tracer uptake. Bone marrow aspiration showed occasional hemophagocytosis, and approximately 13% of total lymphocytes were abnormal, containing vacuolated pink inclusions of varying sizes, referred to as pseudo-Chediak-Higashi anomalies (Fig. 1A-D). These cytoplasmic inclusions were negative for myeloperoxidase staining (Fig. 1E) and positive for periodic acid-Schiff staining (Fig. 1F). Flow cytometric analysis revealed that approximately 7.45% of the abnormal lymphocytes were positive for CD19, CD20, CD22, and CD79b, exhibited restricted expression of immunoglobulin kappa light chain, and were negative for CD5 and CD10. Cytogenetic studies showed a complex karyotype of 45,X,-Y [4] / 45, idem, add(1)(q32), dic(2;9)(p13;p22), t(2;13)(q11.2;p11.2), del(6)(q21), -7, -8, add(9)(p13), del(16)(q22), der(17)t(1;17)(q12;p13), + mar1, + mar2, + mar3 [8] / 46,XY [8]. A bone marrow biopsy confirmed diffuse large B-cell lymphoma (DLBCL). Interestingly, a mucosal biopsy of the gastric body also suggested DLBCL. Consequently, a diagnosis of diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis (HLH) was established, and the patient was treated with induction chemotherapy consisting of cytarabine and idarubicin. Twenty-three days later, the patient developed severe pneumonia, and treatment was discontinued.
Pseudo-Chédiak-Higashi inclusions have been reported in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia, appearing in blasts and mature neutrophils [1, 2, 3–4]. To the best of our knowledge, these have only been described in two cases with mature B-cell tumors. Stoieva et al. reported a case of marginal zone lymphoma with pseudo-Chédiak-Higashi inclusions [5], and Yan et al. described granular inclusions in DLBCL [6]. Notably, in the present case, we observed vacuolated rather than granular pink inclusions within DLBCL lymphocytes, marking the first reported instance of such findings. Although pseudo-Chédiak-Higashi inclusions are relatively easy to identify in bone marrow morphology, they should not be considered evidence of myeloid lineage to guide initial treatment. Additionally, in this case, DLBCL was accompanied by hemophagocytic lymphohistiocytosis (HLH), coexisting with pseudo-Chédiak-Higashi inclusions and a complex karyotype, increasing the complexity of diagnosis and treatment. Timely identification, precise diagnosis, and prompt treatment are essential to improve patient outcomes. However, the mechanisms underlying formation of these vacuolated pink inclusions require further investigation.
No acknowledgements.
Mengying Zeng provide the clinical case and guided the clinical diagnosis. Biyun Yi designed the study and wrote the manuscript. All authors reviewed the manuscript.
None.
No datasets were generated or analysed during the current study.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Changde Hospital, Xiangya School of Medicine, Central South University, Changde, China.
Competing interests
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Blood Res 2025; 60():
Published online January 8, 2025 https://doi.org/10.1007/s44313-024-00052-4
Copyright © The Korean Society of Hematology.
Biyun Yi1 and Mengying Zeng1*
1 Department of Clinical Laboratory, Changde Hospital, Xiangya School of Medicine, Central South University (The First People’s Hospital of Changde City), No. 388, People’s East Road, Changde, Hunan Province 415000, China
Correspondence to:Mengying Zeng
464469565@qq.com
© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
A 75-year-old male was admitted to the hospital with a recurrent fever lasting over a month. Physical examination revealed involuntary tremors in both hands and multiple rashes with apparent bleeding in both lower limbs. Laboratory test results showed leukocytes at 13.1 × 109/L, hemoglobin at 114 g/L, platelets at 108 × 109/L, and elevated levels of lactate dehydrogenase, triglycerides(3.66 mmol/L), ferritin (2745 ng/ml), and soluble interleukin-2 receptor (sIL-2R; 34,170 pg/ml). Fluorodeoxyglucose positron emission tomography (FDG-PET) revealed splenomegaly with increased tracer uptake. Bone marrow aspiration showed occasional hemophagocytosis, and approximately 13% of total lymphocytes were abnormal, containing vacuolated pink inclusions of varying sizes, referred to as pseudo-Chediak-Higashi anomalies (Fig. 1A-D). These cytoplasmic inclusions were negative for myeloperoxidase staining (Fig. 1E) and positive for periodic acid-Schiff staining (Fig. 1F). Flow cytometric analysis revealed that approximately 7.45% of the abnormal lymphocytes were positive for CD19, CD20, CD22, and CD79b, exhibited restricted expression of immunoglobulin kappa light chain, and were negative for CD5 and CD10. Cytogenetic studies showed a complex karyotype of 45,X,-Y [4] / 45, idem, add(1)(q32), dic(2;9)(p13;p22), t(2;13)(q11.2;p11.2), del(6)(q21), -7, -8, add(9)(p13), del(16)(q22), der(17)t(1;17)(q12;p13), + mar1, + mar2, + mar3 [8] / 46,XY [8]. A bone marrow biopsy confirmed diffuse large B-cell lymphoma (DLBCL). Interestingly, a mucosal biopsy of the gastric body also suggested DLBCL. Consequently, a diagnosis of diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis (HLH) was established, and the patient was treated with induction chemotherapy consisting of cytarabine and idarubicin. Twenty-three days later, the patient developed severe pneumonia, and treatment was discontinued.
Pseudo-Chédiak-Higashi inclusions have been reported in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia, appearing in blasts and mature neutrophils [1, 2, 3–4]. To the best of our knowledge, these have only been described in two cases with mature B-cell tumors. Stoieva et al. reported a case of marginal zone lymphoma with pseudo-Chédiak-Higashi inclusions [5], and Yan et al. described granular inclusions in DLBCL [6]. Notably, in the present case, we observed vacuolated rather than granular pink inclusions within DLBCL lymphocytes, marking the first reported instance of such findings. Although pseudo-Chédiak-Higashi inclusions are relatively easy to identify in bone marrow morphology, they should not be considered evidence of myeloid lineage to guide initial treatment. Additionally, in this case, DLBCL was accompanied by hemophagocytic lymphohistiocytosis (HLH), coexisting with pseudo-Chédiak-Higashi inclusions and a complex karyotype, increasing the complexity of diagnosis and treatment. Timely identification, precise diagnosis, and prompt treatment are essential to improve patient outcomes. However, the mechanisms underlying formation of these vacuolated pink inclusions require further investigation.
No acknowledgements.
Mengying Zeng provide the clinical case and guided the clinical diagnosis. Biyun Yi designed the study and wrote the manuscript. All authors reviewed the manuscript.
None.
No datasets were generated or analysed during the current study.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Changde Hospital, Xiangya School of Medicine, Central South University, Changde, China.
Competing interests
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Jin Kyung Suh, Young Kwon Koh, Sung Han Kang, Hyery Kim, Eun Seok Choi, Kyung-Nam Koh, Ho Joon Im
Blood Res 2022; 57(2): 152-157Yu Ri Kim, Dae-Young Kim
Blood Res 2021; 56(S1): S17-S25Hebatallah Adel Sedky, Soha Raouf Youssef, Doaa Ahmad Gamal, Heba Fawzy Houssein, Walaa Ali Elsalakawy
Blood Res 2020; 55(4): 253-261